Renalogic News

Renalogic Expands Leadership Team for Continued Growth

Media Release

Leading cost containment solution for chronic kidney disease attracts top commercial, financial, and technical talent

PHOENIX, AZ and CHICAGO, IL (August 25, 2021) – Renalogic, the leading company helping employers and health plans fight the human and financial costs of chronic kidney disease, announced today the addition of three new executives. Scott Vold has joined the team as Chief Commercial Officer, Forrest Barnes III as Vice President of Data and Technology, and Kyle Bersnak as Vice President of Finance.

Renalogic simultaneously helps clients reduce risk and manage costs by supporting better health outcomes and providing significant savings related to dialysis care. Renalogic’s predictive analytics identify potential risks associated with CKD while the clinically proven Kidney Dialysis Avoidance Program delivers tailored intervention that slows, stops, and in some cases, reverses the trajectory toward dialysis.  For those on dialysis, the company’s proprietary claims repricing methodology provides net savings of up to 85%, which can translate to as much as $1 million per individual.

“Today we have an opportunity to build on our market-leading position and to help more health plans reduce the human and financial costs associated with chronic kidney disease and dialysis claims,” Kevin Weinstein, Renalogic CEO said. “There’s never been a greater need for organizations to bring innovative solutions to help their employees battle chronic diseases and save on healthcare. Scott, Kyle and Forrest have the leadership experience and skills we need to help more people and plans.”

Scott Vold joins Renalogic as the company’s new Chief Commercial Officer. Prior to Renalogic, Vold drove an industry-wide effort to redefine the physician referral management process as Founder and CEO of Fibroblast, Inc., a company he led from concept to successful acquisition by Cerner Corporation in October 2020. Vold began his career as an attorney representing Fortune 1000 companies and financial services firms in complex commercial litigation.

Forrest Barnes III joined Renalogic as the company’s new Vice President of Data and Technology.  Barnes is an Information Technology leader with nearly 20 years’ experience in healthcare, Financial Services, and Insurance sectors. Prior to joining Renalogic, Barnes Served as Director of Information Technologies for Evolution Health, Director of Operations for Blue Cross Blue Shield Insurance and as a Customer Engagement Executive for GuideIt, where he built an enterprise-class background in compliance, security, network architecture, and innovative technology solutions.

Kyle Bersnak was appointed the company’s Vice President of Finance, leveraging more than 15 years of executive finance roles, most recently at one of the largest independent third-party administrators (TPAs) in the United States.  Kyle’s proven history of implementing process improvements and optimizing financial results will benefit all Renalogic clients and partners.

Earlier this summer, Kevin Weinstein was appointed to lead Renalogic as its new Chief Executive Officer. These executive appointments, geared toward better serving clients and growing the company, follow the growth recapitalization with Carrick Capital Partners which was announced in March 2021.

Learn how to fix the risk to your health plan, contact us today.

About Renalogic

Founded in 2002, Renalogic helps self-funded plans of all sizes and their U.S-based health plan members reduce the human and financial costs of chronic kidney disease (CKD) and dialysis treatment. We help plans manage dialysis claims costs and work to prevent members from progressing to dialysis. Through our cost containment and population health management solutions, Renalogic is 230% better than commercial plans at identifying undiagnosed CKD, 86% effective at preventing members from kidney failure and delivers 84.5% average savings off contracted rates with our claims repricing. We’ve saved our clients over $780,000,000 and helped stop CKD from progressing for thousands of members.